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Viruses require host cellular machinery for protein translation and replication. Upon proliferation, virions damage
the cells and are released from the infected cells prior to infecting other cells. Acute inflammation is observed
when host cells are damaged by infection. Receptors for SARS-CoV-2 on cells are distributed more widely than
those specific for other viruses, resulting in a wide range of symptoms such as rhinitis, pneumonia, and enteritis.
Typically, RNA viruses, including SARS-CoV-2, demonstrate high frequencies of gene mutations. Antigenic
modulation due to genetic mutations in the spike protein causes cytokine storms due to strong activation of the
innate immune system. This is similar to the phenomenon previously observed in highly pathogenic avian influ-
enza. The proportion of severely ill patients due to COVID-19 varies from country to country. Factors that are re-
sponsible for the severity of the disease include antibody-dependent enhancement (ADE), BCG (Bacille de Cal-
mette et Guérin) vaccination, and HLA (Human leukocyte antigen) type. ADE and HLA types may also contrib-
ute to the protective effect during an immune reaction including vaccine response against SARS-CoV-2.















いる．Severe acute respiratory syndrome coronavi-
rus 2（SARS-CoV-2）はコロナの呼称の由来となった
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類委員会（International Committee on Taxonomy
of Viruses：ICTV）によると 2019年現在，168の科





































































Figure 1. Structural diagram of SARS-CoV-2.
SARS-CoV-2 is a + ssRNA virus, in which the RNA is cov-
ered with a helical capsid. The envelope derived from the 
infected cell consists of three major glycoproteins, namely, 
spike protein (S), an envelope protein (E), and membrane 
protein (M), and a small number of haemagglutinin ester-
ases (HE), similar to those observed in type C influenza 
virus.
Table　1.　Taxonomy of virus5).















































ds ReoviridaeIG (Rota) 
Virus-derived RNA dependant RNA polymerase is utilized for mRNA synthesis complementary to the genome in single-strand 
(-)RNA virus. Complex capsids include helical and icosahedral structures.
ss, single-stranded; ds, double-stranded; CCHF, Crimea-Congo Hemorrhagic Fever; SFTS, severe fever with thrombocytopenia 
syndrome; JE, Japanese encephalitis; YF, Yellow fever; RS, respiratory syncytial; IG, infectious gastroenteritis; HA, HB, HE, hep-
atitis A, B, E; AIDS, acquired immunodeficiency syndrome; COVID-19, coronavirus disease 2019; ATL, adult T-cell leukemia-

























Figure 2. Life cycle of the coronavirus.
The spike protein binds to the ACE2 enzyme on the plasma membrane of type 2 pneu-
mocytes and intestinal epithelial cells. After binding, the spike protein is cleaved by a host 






















Figure 3. Fc-dependent antibody-dependent enhancement (ADE) hypothesis in SARS-
CoV-2 infection.
Antibody-dependent enhancement (ADE) hypothesis.
A. Specific antibodies targeting viral surface proteins (yellow) bind to and neutralize the 
virus. This promotes viral entry into host phagocytes and blocks their attachment to the 
cell surface viral receptor.
B. Interplay of the cell surface Fc receptor with the viral epitope-bound antibodies pro-
motes viral infection of the target cells (ADE). Incomplete binding of the mutated viral 
ligand (green) to antibodies promotes exposure of the viral epitopes to the cell surface re-
ceptors, leading to enhanced invasion of the virus to the target cells.
C. Viral infection is mediated by host cell surface receptors. Mismatched antibodies are in-

































ure 3-A），ウイルスが貪食されても TMPRSS 2は
Spike Proteinに作用することができず，脱殻は生じ
ない．それに対し変異 Spike Proteinの場合は，前述















































































































Sinovac Inactivated Inactivated 2 0, 14 days IM
Wuhan Institute of Biological
Products/Sinopharm
Inactivated Inactivated 2 0, 21 days IM
Beijing Institute of Biological
Products/Sinopharm
Inactivated Inactivated 2 0, 21 days IM
University of Oxford/AstraZeneca Non-Replicating
Viral Vector
ChAdOx1-S 1 IM




Adenovirus Type 5 Vector 1 IM
Gamaleya Research Institute Non-Replicating
Viral Vector
Adeno-based (rAd26-S+rAd5-S) 2 0, 21 days IM
Janssen Pharmaceutical Companies Non-Replicating
Viral Vector
Ad26COVS1 2 0, 56 days IM
Novavax Protein subunit Full length recombinant SARS 
CoV-2 glycoprotein nanoparticle 
vaccine adjuvanted with Matrix M
2 0, 21 days IM
Moderna/NIAID RNA LNP-encapsulated mRNA 2 0, 28 days IM
BioNTech/Fosun Pharma/Pfizer RNA 3 LNP-mRNAs 2 0, 28 days IM
はウイルス感染を模倣したもので，自然免疫系も刺
激すると同時に細胞性免疫を活性化する type 1
helper T cell（Th1）および液性免疫を活性化する fol-
































1）La Scola B, Audic S, Robert C et al: A giant virus
in amoebae. Science 299: 2033, 2003
2）Philippe N, Legendre M, Doutre G et al: Pan-
doraviruses: amoeba viruses with genomes up to
2.5 Mb reaching that of parasitic eukaryotes. Sci-
ence 341: 281―286, 2013
3）Takemura M: Morphological and taxonomic prop-
erties of Tokyovirus, the first Marseilleviridae mem-
ber isolated from Japan. Microbes Environ 31 (4) :
442―448, 2016
4）Ueki H, Furusawa Y, Iwatsuki-Horimoto K et al:
Effectiveness of Face Masks in Preventing Air-
borne Transmission of SARS-CoV-2. mSphere 5 (5):
e00637-20, 2020, doi: 10.1128/mSphere.00637-20
5）International Committee on Taxonomy of Vi-
ruses: Virus Taxonomy: 2019 Release. https://talk.
ictvonline.org/taxonomy/ ( Accessed October 10,
2020)
6）Imai M, Iwatsuki-Horimoto K, Hatta M et al:
Syrian hamsters as a small animal model for SARS-
CoV-2 infection and countermeasure development.
Proc Natl Acad Sci USA 117 (28): 16587―16595, 2020
7）Munster VJ, Feldmann F, Williamson BN et al:
Respiratory disease in rhesus macaques inoculated
with SARS-CoV-2. Nature 585: 268―272, 2020
―9―
8）Muñoz-Fontela C, Dowling WE, Funnell SGP et
al: Animal models for COVID-19. Nature 586 : 509―
515, 2020, doi: 10.1038/s41586-020-2787-6
9）Rockx B, Kuiken T, Herfst S et al: Comparative
pathogenesis of COVID-19, MERS, and SARS in a
nonhuman primate model. Science 368 : 1012―1015,
2020
10）Coronaviridae Study Group of the International
Committee on Taxonomy of Viruses: The species
Severe acute respiratory syndrome-related coro-
navirus : classifying 2019-nCoV and naming it
SARS-CoV-2. Nat Microbiol 5: 536―544, 2020
11）Konno Y, Kimura I, Uriu K et al: SARS-CoV-2
ORF3b is a potent interferon antagonist whose ac-
tivity is increased by a naturally occurring elonga-
tion variant. Cell Rep 32: 108185, 2020, doi: 10.1016/j.
celrep.2020.108185
12）Kobasa D, Jones SM, Shinya K et al: Aberrant in-
nate immune response in lethal infection of ma-
caques with the 1918 influenza virus. Nature 445 :
319―323, 2007
13）Wrapp D, Wang N, Corbett KS et al: Cryo-EM
structure of the 2019-nCoV spike in the prefusion
conformation. Science 367: 1260―1263, 2020
14）Walls AC, Park Y-J, Tortorici MA et al: Struc-
ture, Function, and Antigenicity of the SARS-CoV-2
Spike Glycoprotein. Cell 181: 281―292.e6, 2020
15）Ishikawa T : Clinical Preparedness for Cytokine
Storm Induced By the Highly Pathogenic H5N1 In-
fluenza Virus. J Pharmacogenom Pharmacopro-
teomics 3 (6 ) : 1000e131, 2012, doi : 10.4172/2153-
0645.1000e131
16）Beigel JH, Farrar J, Han AM et al: Avian influ-
enza A(H5N1)infection in Humans. N Engl J Med
353: 1374―1385, 2005
17）Tumpey TM, Basler CF, Aguilar PV et al: Char-
acterization of the reconstructed 1918 Spanish in-
fluenza pandemic virus. Science 310: 77―80, 2005
18）Imai Y, Kuba K, Neely GG et al: Identification of
oxidative stress and Toll-like receptor 4 signaling
as a key pathway of acute lung injury. Cell 133 :
235―249, 2008
19）Oberfeld B, Achanta A, Carpenter K et al: Snap-
Shot: COVID-19. Cell 181: 954―954.e1, 2020
20）Hoffmann M, Kleine-Weber H, Schroeder S et al:
SARS-CoV-2 Cell Entry Depends on ACE2 and
TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell 181: 271―280.e8, 2020
21）Matsuyama S, Nao N, Shirato K et al: Enhanced
isolation of SARS-CoV-2 by TMPRSS2-expressing
cells. Proc Natl Acad Sci USA 117 (13): 7001―7003,
2020
22）Sungnak W, Huang N, Bécavin C et al: SARS-
CoV-2 entry factors are highly expressed in nasal
epithelial cells together with innate immune genes.
Nat Med 26: 681―687, 2020
23）Isaacs A, Lindenmann J: Virus interference. I. the
interferon. Proc R Soc Lond B Biol Sci 147: 258―267,
1957
24）Wu A, Mihaylova VT, Landry ML : Interference
between rhinovirus and influenza A virus: a clinical
data analysis and experimental infection study.
Lancet Microbe 1 : e254―e262, 2020, doi: 10.1016/S
2666-5247(20)30114-2
25）Takada A, Kawaoka Y : Antibody-dependent en-
hancement of viral infection : molecular mecha-
nisms and in vivo implications. Rev Med Virol 13 :
387―398, 2003
26）Taylor A, Foo S-S, Bruzzone R et al: Fc receptors
in antibody-dependent enhancement of viral infec-
tions. Immunol Rev 268: 340―364, 2015
27）Smatti MK, Al Thani AA, Yassine HM : Viral-
Induced Enhanced Disease Illness. Front Microbiol
9: 2991, 2018
28）Li Q, Wu J, Nie J et al: The Impact of Mutations in
SARS-CoV-2 Spike on Viral Infectivity and Anti-
genicity. Cell 182: 1284―1294.e9, 2020
29）Forster P, Forster L, Renfrew C et al: Phyloge-
netic network analysis of SARS-CoV-2 genomes.
Proc Natl Acad Sci USA 117 (17): 9241―9243, 2020
30）Genomic epidemiology of novel coronavirus
―Global subsampling. 2020. https://nextstrain.org/
ncov/global (Accessed October 10, 2020)
31）Kristensen I, Aaby P, Jensen H : Routine vaccina-
tions and child survival: follow up study in Guinea-
Bissau, West Africa. BMJ 321: 1435―1438, 2000
32）Mihai GN, Jessica Q, Jos WM van der M: Trained
immunity: a memory for innate host defense. Cell
Host Microbe 9: 355―361, 2011
33）Netea MG, Joosten LAB, Latz E et al: Trained im-
munity: A program of innate immune memory in
health and disease. Science 352 (6284): aaf1098, 2016
34）Arts RJW, Moorlag SJCFM, Novakovic B et al:
BCG Vaccination Protects against Experimental Vi-
ral Infection in Humans through the Induction of
Cytokines Associated with Trained Immunity. Cell
Host Microbe 23: 89―100.e5, 2018
35）Khader SA, Divangahi M, Hanekom W et al: Tar-
geting innate immunity for tuberculosis vaccina-
tion. J Clin Invest 129 (9): 3482―3491, 2019
36）Aarreberg LD, Wilkins C, Ramos HJ et al:
Interleukin-1β Signaling in Dendritic Cells Induces
Antiviral Interferon Responses. mBio 9 (2): e00342-
18, 2018
37）Miyasaka M : Is BCG vaccination causally related
to reduced COVID-19 mortality?EMBO Mol Med
12: e12661, 2020, doi: 10.15252/emmm.202012661
38）Miller A, Reandelar MJ, Fasciglione K et al: Cor-
relation between universal BCG vaccination policy
and reduced mortality for COVID-19. medRxiv
2020, doi: 10.1101/2020.03.24.20042937
39）Akiyama Y, Ishida T : Relationship between
COVID-19 death toll doubling time and national
BCG vaccination policy. medRxiv 2020, doi: 10.1101/
2020.04.06.20055251
40）Escobar LE, Molina-Cruz A, Barillas-Mury C :
BCG vaccine protection from severe coronavirus
disease 2019 (COVID-19). Proc Natl Acad Sci USA
117 (30): 17720―17726, 2020
41）Giamarellos-Bourboulis EJ, Tsilika M, Moorlag
―10―
S et al: Activate: Randomized Clinical Trial of BCG
Vaccination against Infection in the Elderly. Cell
183: 315―323.e9, 2020
42）Hamiel U, Kozer E, Youngster I : SARS-CoV-2
Rates in BCG-Vaccinated and Unvaccinated Young
Adults. JAMA 323 (22): 2340―2341, 2020
43）World Health Organization : Bacille Calmette-
Guérin ( BCG ) vaccination and COVID-19. 2020.
https://www.who.int/news-room/commentaries/
detail/bacille-calmette-guérin-(bcg)-vaccination-
and-covid-19 (Accessed October 10, 2020)
44）Tomiyama H, Miwa K, Shiga H et al: Evidence of
presentation of multiple HIV-1 cytotoxic T lympho-
cyte epitopes by HLA-B*3501 molecules that are as-
sociated with the accelerated progression of AIDS.
J Immunol 158: 5026―5034, 1997
45）Kawashima Y, Pfafferott K, Frater J et al: Adap-
tation of HIV-1 to human leukocyte antigen class I.
Nature 458: 641―645, 2009
46）Murakoshi H, Akahoshi T, Koyanagi M et al:
Clinical Control of HIV-1 by Cytotoxic T Cells Spe-
cific for Multiple Conserved Epitopes. J Virol 89
(10): 5330―5339, 2015
47）Keicho N, Itoyama S, Kashiwase K et al: Associa-
tion of human leukocyte antigen class II alleles with
severe acute respiratory syndrome in the Vietnam-
ese population. Human Immunol 70: 527―531, 2009
48）Chen YMA, Liang S-Y, Shih Y-P et al: Epidemi-
ological and genetic correlates of severe acute res-
piratory syndrome coronavirus infection in the hos-
pital with the highest nosocomial infection rate in
Taiwan in 2003. J Clin Microbiol 44 (2 ) : 359―365,
2006
49）World Health Organization : Draft landscape of
COVID-19 candidate vaccines. 2020. https://www.
who.int/publications/m/item/draft-landscape-of-
covid-19-candidate-vaccines (Accessed October 10,
2020)
50）Folegatti PM, Ewer KJ, Aley PK et al: Safety and
immunogenicity of the ChAdOx1 nCoV-19 vaccine
against SARS-CoV-2 : a preliminary report of a
phase 1/2, single-blind, randomised controlled trial.
Lancet 396: 467―478, 2020
51）Zhu F-C, Li Y-H, Guan X-H et al: Safety, tolerabil-
ity, and immunogenicity of a recombinant adenovi-
rus type-5 vectored COVID-19 vaccine : a dose-
escalation, open-label, non-randomised, first-in-
human trial. Lancet 395: 1845―1854, 2020
52）Grifoni A, Weiskopf D, Ramirez SI et al: Targets
of T Cell Responses to SARS-CoV-2 Coronavirus in
Humans with COVID-19 Disease and Unexposed
Individuals. Cell 181: 1489―1501.e15, 2020
